275801-69-9

Upstream product

• 34071-95-9 N-succinimidyl-3-(p-hydroxyphenyl)propionate 
• 73-32-5 L-isoleucine 
• 501-97-3 4-hydroxyphenylpropionic acid 

Downstream Products

• 658053-31-7 N-[3-(4-hydroxyphenyl)propionyl]-L-isoleucyl-L-proline 
• 502761-25-3 1-tert-butoxycarbonylamino-4-{N-[3-(4-hydroxyphenyl)propionyl]-L-isoleucyl-L-prolylamino}butane 
• 658053-32-8 N-[3-(4-hydroxyphenyl)propionyl]-L-isoleucyl-L-proline 2-[4-(tert-butyloxycarbonyl)piperazin-1-yl]ethyl ester 
• 663923-68-0 N-[3-(4-hydroxyphenyl)propionyl]-L-isoleucyl-glycine 
• 663923-69-1 1-(tert-butyloxycarbonylamino)-4-{N-[3-(4-hydroxyphenyl)propionyl]-L-isoleucyl-glycylamino}butane 
• 502761-26-4 RA-1003 
• 502761-23-1 N-[3-(4-hydroxyphenyl)propionyl]-L-isoleucyl-L-proline methyl ester 

Relevant academic research and scientific papers

Synthesis of a cyanopeptide-analogue with trypsin activating properties

An efficient synthesis of a peptidic analogue of cyanobacterial metabolites with proposed serine protease inhibitory activity has been developed. Surprisingly, one trypsin activating compound was obtained. (C) 2000 Elsevier Science Ltd. All rights reserved.

New cyanopeptide-derived low molecular weight thrombin inhibitors

Thrombosis is the result of defective regulation of the hemostasis system. This cardiovascular disorder may lead to deep vein thrombosis, myocardial infarction, and stroke. The majority of current drug research is focused on finding inhibitors of thrombin - the global player in hemostasis. In our work, we emphasize investigation of the marine environment to yield new lead structures from marine organisms like blue-green algae (cyanobacteria). This article deals with the design, syntheses, and inhibition tests of new low molecular weight thrombin inhibitors utilizing cyanopeptides, the secondary metabolites of cyanobacteria with interesting biological activities, as new lead structures. Starting with aeruginosin 98-B (2) as a lead structure, we have developed and synthesized new, selective acting inhibitors of thrombin (RA-1001 and RA-1002), which are suitable targets for further structure-activity studies.

Cyanopeptide analogues: New lead structures for the design and synthesis of new thrombin inhibitors

This contribution deals with the structure-based design and syntheses of the new serine protease inhibitors RA-1001 and RA-1002, which are analogues of the blue-green algae derived cyanopeptide aeruginosin 98-B. Both compounds inhibit thrombin with Ki values of 5.6 μM and 8.7 μM, respectively.